Pentavalent antimonial

PreclinicalSmall molecule

HHospital Universitário Professor Edgard Santos

Pentavalent antimonial is one of 5 small molecule programs targeting Visceral Leishmaniasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Visceral LeishmaniasisActive, not recruiting

Visceral LeishmaniasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Visceral Leishmaniasis

#DrugCompanyPhaseTrials

LXE408

Novartis

Phase 2

3 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Feosol

AAuerbach Hematology Oncology Associates P C

Preclinical

—4

Pentavalent antimonial

HHospital Universitário Professor Edgard Santos

Preclinical

1 5

Amphotericin B Fat Emulsion

BBanaras Hindu University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Visceral Leishmaniasis1 trial

Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine

Unknown status·HHospital Universitário Professor Edgard Santos·N/A·NCT01138956·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pentavalent antimonial. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pentavalent antimonial compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pentavalent antimonial. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Universitário Professor Edgard Santos company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHospital Universitário Professor Edgard Santos

Pentavalent antimonial

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Visceral Leishmaniasis1 trial

References

Drug Info

Quick Facts

Related News